SKAN’s new Cellana isolator is designed for GMP manufacturing of ATMPs.
SKAN’s new Cellana isolator is designed for good manufacturing practice (GMP) manufacturing of advanced therapy medicinal products (ATMPs), particularly GMP manufacturing of cell and gene therapies. A modular design allows different components to be integrated as needed for the specific process, and it can be integrated with semi-automatic or automated filling systems.
The modular Cellana-M series uses predesigned modules and equipment interfaces to deploy different solutions, such as an optional detachable incubator interface. Rapid transfer options allow secure transfer of living cells and other fragile material without damage from sterilants or cryopreservatives.
The Cellana-L series provides flexibility and scalability using an L-flange design. The L-flange has been adapted to interface with complex lab equipment and processes, as well as robotic aseptic vial filling equipment, such as the Crystal Cellana L1 technology that processes the Ready-to-fill AT-Closed Vials. This design can take product from initial cells to final product in one isolator system.
The isolators use technology already established in SKAN’s other isolators, such as the skanfog decontamination technology and a catalytic convertor that completely decomposes hydrogen peroxide before the air is exhausted. This technology reduces the use of hydrogen peroxide and eliminates its waste stream.
Source: SKAN
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.